Discrepancies between CSF biomarker and PET determinations of elevated brain amyloid and their prognostic significance.

ABSTRACT:

Introduction

When cerebrospinal fluid (CSF) and positron emission tomography (PET) measurements for amyloid-beta-peptide (Aβ) related pathology are discordant, therapeutic decision-making becomes uncertain.

Methods

Using data from patients with mild cognitive impairment (n = 541) from the Alzheimer's Disease Neuroimaging Initiative, we examined baseline characteristics and longitudinal clinical outcomes in persons grouped according to normal/abnormal Aβ via concurrent CSF and PET determinations using standard cutpoints.

Results

Discordant groups for brain Aβ status (CSF+/PET- and CSF-/PET+) each represented about 5% of the mild cognitive impairment (MCI) population. Longitudinally, neither discordant group declined more than the CSF-/PET- group on either a memory meas

SUBMITTER: Knopman DS 

PROVIDER: S-EPMC12441586 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature